Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.

Autor: Rassy E; Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, Villejuif, France., Filleron T; BiostatisticsDepartment, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France., Viansone A; Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, Villejuif, France., Lacroix-Triki M; Department of Biopathology, University of Paris Saclay, Roussy, Villejuif, France., Rivera S; Department of Radiation Therapy, University of Paris Saclay, Gustave Roussy, Villejuif, France., Desmoulins I; Department of Medical Oncology, Centre Oscar Lambret, Lille, France., Serin D; Department of Medical Oncology, Institut Sainte-Catherine, Avignon, France., Canon JL; Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgium., Campone M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site René Gauducheau, Site Hospitalier Nord, Saint-Herblain, France., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Levy C; Department of Medical Oncology, Centre François Baclesse, Caen, France., Cottu P; Department of Medical Oncology, Institut Curie, Paris, France., Petit T; Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France., Eymard JC; Department of Medical Oncology, Institut Godinot, Reims, France., Debled M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Bachelot T; Department of Medical Oncology, Centre Leon Berard, Lyon, France., Dalenc F; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire Cancer Toulouse-Oncopole, Toulouse, France., Roca L; Institut Régional du Cancer de Montpellier, Parc Euromédecine, Montpellier, France., Lemonnier J; R&D UNICANCER, UCBG, Paris, France., Delaloge S; Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, Villejuif, France., Pistilli B; Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, Villejuif, France. barbara.pistilli@gustaveroussy.fr.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Jun; Vol. 199 (2), pp. 371-379. Date of Electronic Publication: 2023 Mar 29.
DOI: 10.1007/s10549-023-06912-4
Abstrakt: Purpose: We aimed to determine the pattern of isolated local recurrences (ILR) in women with stage II-III hormone receptor-positive and human epidermal growth factor receptor 2 breast cancer (HR + /HER2-BC) after 10-year follow-up.
Methods: UNICANCER-PACS 01 and PACS 04 trials included 5,008 women with T1-T3 and N1-N3 to evaluate the efficacy of different anthracycline ± taxanes-containing regimens after modified mastectomy or lumpectomy plus axillary lymph node dissection. We analyzed the data from 2,932 women with HR + /HER2- BC to evaluate the cumulative incidence of ILR and describe the factors associated with ILR.
Results: After a median follow-up of 9.1 years (95% CI 9.0-9.2 years), the cumulative incidence of ILR increased steadily between 1 and 10 years from 0.2% to 2.5%. The multivariable analysis showed that older age (subhazard ratios [sHR] = 0.95, 95% CI 0.92-0.99) and mastectomy (sHR = 0.39, 95% CI 0.17-0.86) were associated with lower risk of ILR, and no adjuvant endocrine therapy (sHR = 2.73, 95% CI 1.32 7-5.67) with increased risk of ILR.
Conclusion: In this population of high-risk patients with localized HR + /HER2- BC, the risk of ILR was low but remained constant over 10 years. Younger age at diagnosis, breast-conserving surgery, and adjuvant endocrine therapy were independent risk factors of ILR.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: